Key Drivers
- Liquidity Improved
- Leverage Reduced
- Cash Flow Weak
AIAI Summary
ACA is now primarily a merger-arbitrage trade: buying near $145–146 offers only ~$4–5 of capped upside to CRH's $150 cash bid, while regulatory, litigation, and weak recent cash conversion create materially larger downside if the deal breaks—so investors should own it only if comfortable underwriting closing risk rather than standalone growth.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Improved
- •Leverage Reduced
- •Cash Flow Weak
ACA's stronger liquidity, lower leverage, and cheaper earnings valuation support the outlook, but investors should remain cautious of distorted quarterly profits and negative recent cash flow.
Price Behavior
Key Price Behavior Insights:
- •Late-period advance
- •Narrow trading range
- •Breakout confirmation
ACA was modestly bullish over the last month, reaching 145.84 with constructive momentum, but needs a sustained break above 146.00 while holding 145.00 support.
Late rise to a new short-term high amid limited overall gains
Sentiment & News
Key News Insights:
- •Merger approval
- •Dividend maintained
- •Institutional buying
Arcosa advances toward CRH acquisition approval while maintaining its dividend and drawing institutional interest, though final vote certification is pending.
The acquisition progress is a positive catalyst for Arcosa shares, subject to final voting confirmation and deal completion
Similar Companies in Industrials
Other companies in the same sector with AI ratings